

Keyword Index for Volume 33

A

Ab initio, 253
N-Acetylmannosamine, 216
N-Acetylneuraminic acid, 216
 α_1 -Acid glycoprotein, 298
 β -Adrenergic blocking agents, 310
 β -Adrenergic receptor binding, 310
Aflatoxicity test, 426
Aflatoxin, 426
Aldol reaction, 116
Amine dehydrogenase, 159
Amino acids, 16
Aminocyclitol antibiotics, 82
Aminoglycoside antibiotics, 149
4-Amino-2-methyl-5-hydroxymethylpyrimidine
kinase, 338
Anthraquinone Pigment, 426
Antibiotic resistance, 149
Antileishmanial activity, 439
Antioxidant, 108
Antitumor agents, 1
Aryltetralin, 484
Aspergillus flavus, 426
Atenolol, 310

B

Benzene, 363
Benzoylformate decarboxylase, 190
Binding discrimination, 45
Biofluids, 415
Biosynthesis, 216
Biosynthetic intermediates, 426
Bixin, 298
Breast cancer, 1
 γ -Butyrolactone, 53

C

C2 α -carbanion or enamine, 190
C2 α -hydroxyethylthiamin diphosphate, 190

C2 α -lactylthiamin diphosphate, 190
Calixarenes, 16
Candida antarctica lipase, 22
Cardiolipin, 345
cis-Carotenoid, 298
Catalysis, 16
Catechin, 108
Cationic lipids, 345
Cdc25, 264
Cdk, 264
Cell-growth inhibition activity, 22
Circular dichroism, 190
Circular dichroism spectroscopy, 298
Cleavage, 374
Coenzyme A, 90
Cofactor regeneration, 171
Cofactors, 90
Conformational analyses, 484
Connectivity effect, 45
Coupling reagent, 386
Cyclin, 264

D

Dehydrogenase, 171
Density functional, 274
Density functional theory, 108, 253
2-Deoxy-*scyllo*-inosose synthase, 82
12,13-Desoxyepothilone B, 116
DFT calculations, 484
Diabetes mellitus, 34
Diastereoselective alkylation, 116
Dihydroorotase inhibitors, 470
5,7-Dihydroxy-4-methylcoumarin, 67
7,8-Dihydroxy-4-methylcoumarin, 67
Dinuclear complexes, 374
Diphenyl phosphite, 386
Docking, 274
DU-145 cells, 22
Dual specificity phosphatase, 34

E

Editing, 229
Effective molarity, 45
Enantioselectivity, 325
Enzyme catalysis, 90
Epothilone D, 116
EPR spectroscopy, 53
Estradiol, 1

F

Ferulic acid, 325
Feruloyl esterase, 325
Flavin adenine dinucleotide semiquinone, 53
Fluorinase, 393
5'-Fluoro-5'-deoxyadenosine, 393
5'-Fluoro'-deoxyinosine, 393
Fluoroacetate, 393
Fluorometabolite, 393
4-Fluorothreonine, 393
Formylglycinamide, 253

G

Gallic acid, 67
Gene delivery, 345
GIAO calculations, 484
Glutathione, 363

H

Hindered peptide, 386
Hemicola insolens, 325
Hybrid estradiol-Pt(II) complexes, 1
Hydrazide, 459
Hydrazine, 459
Hydride transfer, 82
Hydrogen tunneling, 159
4-Hydroxybutyryl-CoA dehydratase, 53
Hydroxyl bond dissociation enthalpy, 108
Hydroxyl proton dissociation enthalpy, 108

I

1',4'-Imino tautomer, 190
Induced chirality, 298
Inhibitor, 285
Insulin signaling, 34
Ionization potential, 108
Isoaspartyl dipeptidase, 448
Isomerization, 363
Isotopic labeling, 53

K

Kinase, 285

L

Lactone, 484
Lignans, 484
Lipase resolution, 116
Lipid-based formulations, 345
Lipocalin, 298

M

Macrocyclic polyamine, 374
MAP kinase, 34
Maximum hardness principle, 253
Mechanism, 216
Mechanism of phosphate transfer, 149
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 402
Modification, 229
Molecular interaction field, 274
Molecular rotors, 415
Morelensin, 484
(*E,E*)-Muconaldehyde, 363
Mutagenicity, 402

N

NAD⁺, 82
NF- κ B inhibitors, 67
Nonplanarity, 253
Nucleosides, 439
Nucleotide, 285

O

ODCase, 45
OMP, 45
OMP decarboxylase, 45
Orotidine, 45
Oxidative cascades, 136
1-Oxo-isoindoline, 310
Oxygen radicals, 459

P

p50 protein, 67
Parkinson's disease, 402
Peptide bond, 253
Peptides, 16, 285
pH-dependence, 264
Phenoxypropanolamines, 310
Phosphatase, 264
Phosphite, 171
Phosphoenolpyruvate, 216
Phosphoryl transfer, 171
Platinum(II) complexes, 1
Polygamain, 484
Posttranslational modification, 159
Propranolol, 310
Prostate cancer, 22

Protein, 285
 Protein degradation, 459
 Protein-derived cofactor, 159
 Protein tyrosine phosphatase superfamily, 34
 Pseudouridine, 229
 pUC 19 DNA, 374
 Pyruvate dehydrogenase complex, 190

Q

Queuosine, 229
 Quinoprotein, 159

R

Red shift, 298
 Redox protein, 159
 Resveratrol, 22
 RNA, 229

S

Secondary alcohols, 325
 Secondary amine, 386
 Sialic acid synthase, 216
 Solid-phase synthesis, 16
 Solvent effect, 108
 Stacking complexes, 402
 Stereospecificity, 82
 Substrate analogue inhibitor, 470
 Suzuki coupling, 116
 Synthesis, 22

T

1,4,7,10-Tetraazacyclododecane (cyclen), 374
 Thiamin, 338
 Thiaminase II, 338
 Thiamin biosynthesis, 338
 Thiamin degradation, 338
 Thiamin diphosphate, 190
 Thiamin metabolism, 338
 Thiol adducts, 363
 Thiophosphate, 264
 TICT, 415
 Transesterification, 325
 Transfection, 345
 Transglycosylation, 229
 Transition state, 45
 1,2,3-Trimethylxanthine, 402
 Type 2 diabetes, 34

U

UDP-GlcNAc 2-epimerase, 216

V

Viscosity, 415

Y

Yeast pyruvate decarboxylase,
 190
 Ylide/C2-carbanion, 190